238 reports of this reaction
1.4% of all AMISULPRIDE reports
#15 most reported adverse reaction
WHITE BLOOD CELL COUNT INCREASED is the #15 most commonly reported adverse reaction for AMISULPRIDE, manufactured by Acacia Pharma Ltd. There are 238 FDA adverse event reports linking AMISULPRIDE to WHITE BLOOD CELL COUNT INCREASED. This represents approximately 1.4% of all 16,736 adverse event reports for this drug.
Patients taking AMISULPRIDE who experience white blood cell count increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WHITE BLOOD CELL COUNT INCREASED is a less commonly reported adverse event for AMISULPRIDE, but still significant enough to appear in the safety profile.
In addition to white blood cell count increased, the following adverse reactions have been reported for AMISULPRIDE:
The following drugs have also been linked to white blood cell count increased in FDA adverse event reports:
WHITE BLOOD CELL COUNT INCREASED has been reported as an adverse event in 238 FDA reports for AMISULPRIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
WHITE BLOOD CELL COUNT INCREASED accounts for approximately 1.4% of all adverse event reports for AMISULPRIDE, making it a notable side effect.
If you experience white blood cell count increased while taking AMISULPRIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.